Lanthaler

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

Retrieved on: 
Monday, April 19, 2021
Evotec, Lanthaler

Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong.

Key Points: 
  • Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong.
  • We intend to fast track a phase I clinical trial of the drug, which we expect to commence in CY2021.
  • "\nHe added, "As we have built Kazia over the past five years, our strategy has been to assemble a portfolio of world-class development candidates through in-licensing.
  • "\nEvotec CEO, Dr Werner Lanthaler, commented, "we are very pleased to partner with Kazia for this promising asset, for which we have high hopes.

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

Retrieved on: 
Monday, April 19, 2021
Evotec, Lanthaler

Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong.

Key Points: 
  • Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong.
  • We intend to fast track a phase I clinical trial of the drug, which we expect to commence in CY2021.
  • "\nHe added, "As we have built Kazia over the past five years, our strategy has been to assemble a portfolio of world-class development candidates through in-licensing.
  • "\nEvotec CEO, Dr Werner Lanthaler, commented, "we are very pleased to partner with Kazia for this promising asset, for which we have high hopes.

DGAP-News: EVOTEC INITIATES 'CAMPUS CURIE' IN TOULOUSE

Retrieved on: 
Wednesday, July 8, 2020
Evotec, Toulouse, Lanthaler, Geography of France, Companies

As of 01 July 2020, Evotec has acquired 100% of the shares of BBS which will be named to "Campus Curie" going forward.

Key Points: 
  • As of 01 July 2020, Evotec has acquired 100% of the shares of BBS which will be named to "Campus Curie" going forward.
  • Set in the life sciences research area "Oncopole", BBS owns and manages the Toulouse site at which Evotec has been the major tenant since acquiring Sanofi's Toulouse-based scientific operations in 2015.
  • Since then, the number of employees at Evotec's Toulouse site has almost tripled to approximately 600.
  • Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "Evotec is strongly committed to creating sustainable growth opportunities at all of our international sites.

Celmatix Expands Strategic Partnership with Evotec in Women’s Health

Retrieved on: 
Tuesday, December 3, 2019
Health, Consumer, Women, Other Health, Clinical trials, General Health, Evotec, Lanthaler, Oregon Manufacturing Innovation Center

This kind of precision health has been revolutionary for categories like oncology, and we are excited about the impact that our alliance with Evotec will have on the field of womens reproductive health.

Key Points: 
  • This kind of precision health has been revolutionary for categories like oncology, and we are excited about the impact that our alliance with Evotec will have on the field of womens reproductive health.
  • Evotec CEO Werner Lanthaler commented, Over the last 10 years, Celmatix has built the largest, proprietary multi-omic datasets and multidisciplinary expertise in womens reproductive health.
  • Celmatix is changing the paradigm for womens health, and we are thrilled to be a part of that remarkable endeavor.
  • Life Sciences Innovation Fund portfolio manager David Sable, MD commented, The data platform created by Celmatix is unmatched in womens health.